Hard To Treat Stock Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Hard To are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Hard to Treat has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Hard To is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Total Cashflows From Investing Activities | -1.7 M |
Hard |
Hard To Relative Risk vs. Return Landscape
If you would invest 0.00 in Hard to Treat on September 23, 2024 and sell it today you would earn a total of 0.00 from holding Hard to Treat or generate 0.0% return on investment over 90 days. Hard to Treat is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Hard, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Hard To Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hard To's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Hard to Treat, and traders can use it to determine the average amount a Hard To's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| HTDS |
Based on monthly moving average Hard To is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hard To by adding Hard To to a well-diversified portfolio.
Hard To Fundamentals Growth
Hard Stock prices reflect investors' perceptions of the future prospects and financial health of Hard To, and Hard To fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hard Stock performance.
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 254.37 K | ||||
| Shares Outstanding | 5.48 B | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 5.39 M | ||||
| Gross Profit | 1.42 M | ||||
| EBITDA | 1.03 M | ||||
| Net Income | 621.6 K | ||||
| Cash And Equivalents | 202.9 K | ||||
| Total Debt | 1.54 M | ||||
| Debt To Equity | 0.21 % | ||||
| Cash Flow From Operations | 655.71 K | ||||
| Total Asset | 4.56 M | ||||
| Retained Earnings | 1.4 M | ||||
| Current Asset | 596 K | ||||
| Current Liabilities | 1.1 M | ||||
About Hard To Performance
Assessing Hard To's fundamental ratios provides investors with valuable insights into Hard To's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Hard To is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China. Hard To operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Hard to Treat performance evaluation
Checking the ongoing alerts about Hard To for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hard to Treat help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hard to Treat generated a negative expected return over the last 90 days | |
| Hard to Treat has some characteristics of a very speculative penny stock | |
| Hard to Treat has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Affimeds AFM28 Shows 40 percent Complete Remission Rate in Hard-to-Treat Leukemia Trial - StockTitan |
- Analyzing Hard To's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hard To's stock is overvalued or undervalued compared to its peers.
- Examining Hard To's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hard To's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hard To's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hard To's stock. These opinions can provide insight into Hard To's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Hard Stock Analysis
When running Hard To's price analysis, check to measure Hard To's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hard To is operating at the current time. Most of Hard To's value examination focuses on studying past and present price action to predict the probability of Hard To's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hard To's price. Additionally, you may evaluate how the addition of Hard To to your portfolios can decrease your overall portfolio volatility.